摘要
孕激素受体(PR)是一种配体激活类固醇激素受体的核受体(NR)家族的转录因子。除了妇科和产科指征,PR在许多其他疾病的介入/机制中,如肿瘤、神经、免疫、等已在近几十年来的研究中被发现。已开发的治疗剂可以有选择性地激活或抑制PR。PR受体激动剂通常结合雌激素被用于口服避孕药和绝经后激素替代疗法(HRT)。PR受体拮抗剂和选择性的PR调节剂(SPRMs)可以对激素依赖性乳腺癌,前列腺癌以及非恶性慢性疾病,如子宫肌瘤、子宫内膜异位症等产生有效的治疗。本综述将提供一个概述和详细的关于最近发展的化学结构的共同配体,它们的结构特点(特别是那些有助于他们的活性和选择性的),以及在体外/体内研究和临床试验结果和合成方法。
关键词: 激动剂;拮抗剂;配体;调制器;非甾体类激素;孕激素受体;类固醇。
Current Medicinal Chemistry
Title:Current Progresses and Trends in the Development of Progesterone Receptor Modulators
Volume: 23 Issue: 23
Author(s): Wenlu Li, Xi Li, Bin Zhang, Chunmei Gao, Yuzong Chen, Yuyang Jiang
Affiliation:
关键词: 激动剂;拮抗剂;配体;调制器;非甾体类激素;孕激素受体;类固醇。
摘要: The progesterone receptor (PR) is a ligand-activated steroid receptor in the nuclear receptor (NR) superfamily of transcription factor. Besides gynecological and obstetrical indications, the involvement/mechanism of PR in many other diseases, such as oncology, neurology, immunology, etc. has been revealed and studied in recent decades. Therapeutic agents that selectively activate or inhibit PR have been developed. PR agonists have generally been used in oral contraception and postmenopausal hormone replacement therapy (HRT), typically in combination with estrogens. PR antagonists and selective PR modulators (SPRMs) can be useful therapies for hormone dependent breast and prostate cancers, nonmalignant chronic conditions such as fibroids, and endometriosis. This review provides an overview and detailed discussions about the recent development of chemical structures of the PR ligands, their structural characteristics (particularly those contributing to their activity and selectivity), in vitro/in vivo studies and clinical trial outcomes, and the synthetic methodologies.
Export Options
About this article
Cite this article as:
Wenlu Li, Xi Li, Bin Zhang, Chunmei Gao, Yuzong Chen, Yuyang Jiang , Current Progresses and Trends in the Development of Progesterone Receptor Modulators, Current Medicinal Chemistry 2016; 23 (23) . https://dx.doi.org/10.2174/0929867323666160428105310
DOI https://dx.doi.org/10.2174/0929867323666160428105310 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Novel Proteins and Pathways as Anti-Cancer Therapeutic Targets (Guest Editor: Q. Ping Dou)]
Current Protein & Peptide Science P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, Microemulsions and Dendrimers
Current Pharmaceutical Biotechnology Extracellular Citrate in Health and Disease
Current Molecular Medicine Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins
Current Molecular Medicine Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Cadmium as an Endocrine Disruptor in the Reproductive System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Antibody Immobilization Techniques in Mass Sensitive Immunosensor: Enhanced Sensitivity through Limited Mass Load
Current Analytical Chemistry The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Bone: A Fertile Soil for Cancer Metastasis
Current Drug Targets The Chance of Small Interfering RNAs as Eligible Candidates for a Personalized Treatment of Prostate Cancer
Current Pharmaceutical Biotechnology Discovery of New Biomarkers of Cancer Using Proteomics Technology
Current Cancer Therapy Reviews What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?
Current Women`s Health Reviews The Potential of Flavonolignans in Prostate Cancer Management
Current Medicinal Chemistry